Asami Minamibata1, Yoshihito Kono2, Taichiro Arimoto2, Yoshinori Marunaka2, Koichi Takayama3. 1. Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan; asami-minamibata@hokenkai.jp. 2. Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan. 3. Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Abstract
BACKGROUND/AIM: Lung cancer is a frequent and fatal cancer that is difficult to diagnose in the early stages. CYFRA 21-1 is a serological marker currently used to diagnose and monitor lung cancer; however, its clinical use for screening is controversial. Therefore, the present study investigated the relationship between serum CYFRA 21-1 levels and clinical confounders. PATIENTS AND METHODS: We recruited 3,674 individuals who had never been diagnosed with any cancer. The relationships between high serum CYFRA 21-1 levels (≥3.5 ng/ml) and age, sex, body mass index, and smoking status were investigated. RESULTS: High serum CYFRA 21-1 levels (≥3.5 ng/ml) were detected in 5.1% of all subjects. High serum CYFRA 21-1 levels were observed in 7.3% of current smokers and 4.3% of non-smokers. The proportion of subjects with high serum CYFRA 21-1 levels was markedly higher in the older group (65 years and older, 11%) than in the younger group (younger than 45 years, 2.0%). High serum CYFRA 21-1 levels (≥3.5 ng/ml) were associated with older age [odds ratio (OR)=3.39, 95% confidence interval (CI)=1.79-6.41 for 55-64 years vs. <45 years, and OR=7.34, 95% CI=3.86-13.9 for ≥65 years vs. <45 years, respectively] and current smoking (OR=2.09, 95% CI=1.38-3.15 for current smoker vs. non-smoker). CONCLUSION: High serum CYFRA 21-1 levels were associated with an older age and current smoking, which may be considered as factors influencing CYFRA 21-1 levels.
BACKGROUND/AIM: Lung cancer is a frequent and fatal cancer that is difficult to diagnose in the early stages. CYFRA 21-1 is a serological marker currently used to diagnose and monitor lung cancer; however, its clinical use for screening is controversial. Therefore, the present study investigated the relationship between serum CYFRA 21-1 levels and clinical confounders. PATIENTS AND METHODS: We recruited 3,674 individuals who had never been diagnosed with any cancer. The relationships between high serum CYFRA 21-1 levels (≥3.5 ng/ml) and age, sex, body mass index, and smoking status were investigated. RESULTS: High serum CYFRA 21-1 levels (≥3.5 ng/ml) were detected in 5.1% of all subjects. High serum CYFRA 21-1 levels were observed in 7.3% of current smokers and 4.3% of non-smokers. The proportion of subjects with high serum CYFRA 21-1 levels was markedly higher in the older group (65 years and older, 11%) than in the younger group (younger than 45 years, 2.0%). High serum CYFRA 21-1 levels (≥3.5 ng/ml) were associated with older age [odds ratio (OR)=3.39, 95% confidence interval (CI)=1.79-6.41 for 55-64 years vs. <45 years, and OR=7.34, 95% CI=3.86-13.9 for ≥65 years vs. <45 years, respectively] and current smoking (OR=2.09, 95% CI=1.38-3.15 for current smoker vs. non-smoker). CONCLUSION: High serum CYFRA 21-1 levels were associated with an older age and current smoking, which may be considered as factors influencing CYFRA 21-1 levels.
Authors: H Nakamura; S Abe; Y Shibata; H Yuki; H Suzuki; H Saito; M Sata; S Kato; H Tomoike Journal: Am J Respir Crit Care Med Date: 1997-04 Impact factor: 21.405
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk Journal: N Engl J Med Date: 2020-01-29 Impact factor: 91.245
Authors: P Stieber; U Hasholzner; H Bodenmüller; D Nagel; L Sunder-Plassmann; H Dienemann; W Meier; A Fateh-Moghadam Journal: Cancer Date: 1993-08-01 Impact factor: 6.860
Authors: Sonia Blanco-Prieto; Loretta De Chiara; Mar Rodríguez-Girondo; Lorena Vázquez-Iglesias; Francisco Javier Rodríguez-Berrocal; Alberto Fernández-Villar; María Isabel Botana-Rial; María Páez de la Cadena Journal: Sci Rep Date: 2017-01-24 Impact factor: 4.379